On the stock market since 2020, it operates in the world of health and science. It has 155 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
The cash pile is strong; debt and other items pull the grade toward the middle.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
The price is looking for direction — no strong breakout, no collapse.
Growth: Sales growth trails the sector average.
Business Quality: Profit power and business quality trail similar companies in the sector.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Executive Buying: The trades send no strong signal of confidence.
The stock trades 20% below its peak. The market has trimmed its expectations for the company.
There is $791.2M in the vault; even if every debt were paid off, $789.3M would remain.
The average analyst price target is $102 — 34% above today’s price.
A loss of $212.2M against $0 in annual sales.
This stock swings about 2.1 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, IRON sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: IRON is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Analysts’ average target sits above today’s price, yet the valuation grade (50/100) says the stock isn’t cheap.